<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, treatment of severe COVID-19 patients with the HIV protease inhibitors lopinavir-ritonavir had no obvious efficacy beyond standard care
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref> but the final determination of their efficacy for COVID-19 patients requires further clinical study
 <xref rid="CIT0023" ref-type="bibr">
  <sup>23</sup>
 </xref>. The use of hydroxychloroquine sulphate, an antimalarial agent, in severe or critically ill COVID-19 patients showed contradictory results in clinical trials
 <xref rid="CIT0024" ref-type="bibr">
  <sup>24</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0025" ref-type="bibr">
  <sup>25</sup>
 </xref>, and it is suggested to be more effective in early infection. Remdesivir, a nucleotide analogue prodrug in phase III clinical trials for Ebola virus infection, showed therapeutic promise for treating severe COVID-19 patients, with shortened recovery times
 <xref rid="CIT0026" ref-type="bibr">
  <sup>26â€“28</sup>
 </xref>. Dexamethasone, a corticosteroid, was found to reduce the 28-day mortality of COVID-19 patients receiving either invasive mechanical ventilation or oxygen alone
 <xref rid="CIT0029" ref-type="bibr">
  <sup>29</sup>
 </xref>. Based on the therapeutic experience against viruses, the most effective therapy for SARS-CoV-2 infection would most likely require a cocktail of agents targeting different stages of viral infection
 <xref rid="CIT0030" ref-type="bibr">
  <sup>30</sup>
 </xref>. Indeed, combining lopinavir-ritonavir with two other agents helped alleviate symptoms, and a shortened viral shedding period was reported in mild-to-moderate COVID-19 patients
 <xref rid="CIT0010" ref-type="bibr">
  <sup>10</sup>
 </xref>.
</p>
